[ad_1]
“Confirmation that vaccine candidates elicit antibody responses”
One study found that the first vaccine against new coronavirus infection (Corona 19) approved in Russia, ‘Putnik V’, triggered an immune response.
Sputnik finished the initial clinical trial in two months and did not go through final phase 3, so there were concerns that it would be approved quickly.
According to CNN on the 4th (local time), the initial clinical results of Sputnik were released in the medical journal ‘The Lancet’.
According to the Lancet, the researchers conducted primary and secondary clinical trials in 38 healthy adults ages 18 to 60, respectively, at two Russian hospitals in June and July. As a result, corona19 antibodies were produced in all participants.
The second vaccination took place 21 days after the first clinical vaccination. The test lasted 42 days. No placebo (a dummy drug) was given, although side effects such as mild fever did occur, but generally insignificant.
“We couldn’t find any serious side effects. And we confirm that vaccine candidates elicit an antibody response. “
The researchers collected convalescent plasma from 4,817 people who recovered from mild Corona 19 and compared their immunity to innate immunity after vaccination. As a result, the antibody response after vaccination was higher.
Neutralizing antibody reactions were observed in all participants in Phase 2 In the case of Phase 1 participants who received only one vaccine, only 61% of participants showed neutralizing antibody reactions. This was similar to the immune response you have after naturally recovering from Corona 19.
In addition, the researchers observed reactions related to T cells, which are immune cells.
The researchers said: “It appears that the vaccine can trigger a T-cell response in 28 days.”
The researchers noted that the clinical scale was small, the trial period was short, and that only men participated in the first trial. The age group also focused on the relatively healthy 20s and 30s.
Kiril Dmitryev, chief executive of RDIF, a Russian sovereign wealth fund that supported vaccine development, said the announcement was a turning point for the attack on the Sputnik project.
“We are proud to have the best vaccines in the world,” he said.
CNN said this announcement should not be prematurely concluded with a successful vaccine development. Other experts who were not involved in the study believe the results are positive, but large-scale Phase III results involving tens of thousands of people are needed to be sure that the vaccine actually prevents COVID-19.
Russia is scheduled to start Sputnik clinical trials on the 5th. The experiment, involving 40,000 people, will be carried out in about 20 Moscow hospitals.
[서울=뉴시스]Copyright by dongA.com All rights reserved.
